


cat-ELCCA: A Robust Method To Monitor the Fatty Acid Acyltransferase Activity of Ghrelin O-Acyltransferase (GOAT)**

Amanda L. Garner and Kim D. Janda*




Assays armed with catalytic signal amplification have arisen as superior systems for ultrasensitive detection of analytes.^[1,2] In the biocatalysis field, while fluorogenic and colorimetric enzyme assays designed to examine cleavage reactions have taken advantage of this strategy,^[3] many important enzyme classes, including acyltransferases, have mechanistically been excluded from such analytical techniques. As a result, the visualization of activity for these enzymes (i.e. addition of a post-translational modification) typically relies on autoradiographic methods, which are often not high-throughput and are hazardous, precluding library-based screening against these targets.^[4] For example, in the acyltransferase field, [³H]-labeled fatty acids have traditionally been utilized to detect protein fatty acid acylation using liquid scintillation counting, although exceptions have been reported.^[5] Despite these efforts, high-throughput, fluorescence-based assays still remain highly sought after in this field.

As an alternative approach, several groups have recently reported the use of click-chemistry-based approaches utilizing azido- and alkynyl-tagged fatty acids for the nonradioactive detection of protein fatty-acylation in living cells.^[6] In specific, the use of Cu^I-catalyzed Huisgen [3+2] cycloaddition chemistry^[7] has proved to be a robust detection method for such efforts. Interestingly, while click chemistry has found widespread success in activity-labeling approaches such as those described above, bioconjugation efforts^[8] and enzyme inhibitor discovery,^[9] it has yet to be utilized in the development of high-throughput screening assays, despite its biological and chemical compatibility and near-quantitative yields.^[7c] Herein, we describe our efforts toward the development of a click-chemistry-based, high-throughput screen to monitor acyltransferase activity.

Inspired by enzyme immunoassays,^[10] in particular cat-ELISA (catalytic assay using ELISA),^[11] we sought to design an acyltransferase assay that takes advantage of the catalytic signal amplification obtained with enzyme-linked detection antibodies. In cat-ELISA (Figure 1A), a solid-supported substrate is first treated with a catalytic antibody (or enzyme) to obtain a product, which is subsequently bound with a product-specific antibody. This antibody is then detected with an enzyme-linked secondary antibody, the enzyme of which catalyzes the turnover of a fluorescent or colorimetric substrate in solution to provide signal amplification necessary for sensitive quantitation.

A) cat-ELISA



B) cat-ELCCA




Figure 1. Comparison of A) cat-ELISA and B) catalytic assay using enzyme-linked click-chemistry assay (cat-ELCCA). E = enzyme. S = substrate.

Taking a similar approach, we proposed to immobilize an acyltransferase-recognized, biotinylated peptide fragment to a streptavidin microtiter plate. This immobilized peptide would then be incubated with an alkynyl-tagged fatty acid in the presence of the enzyme (Figure 1B). Following this enzyme-catalyzed acyl transfer, the tagged fatty acid ester would then be converted to the enzyme-linked 1,2,3-triazole using an azido-tagged enzyme by Cu^I-catalyzed Huisgen [3+2] cycloaddition chemistry.^[12] Subsequent addition of a fluorogenic substrate of the linked enzyme would provide catalytic signal amplification. To keep with the terminology of cat-ELISA, we have named this assay technology catalytic assay using enzyme-linked click-chemistry assay (cat-ELCCA).

As a model enzyme to demonstrate this technology, we chose to examine the recently disclosed acyltransferase, ghrelin-*O*-acyltransferase (GOAT).^[13] This membrane-bound *O*-acyltransferase (MBOAT)^[14] family member catalyzes the *n*-octanoylation of ghrelin (Figure 2), a 28-amino acid growth-hormone-releasing peptide implicated in feeding, weight gain, and the regulation of energy homeostasis, and identified as a leading anti-obesity drug target.^[15] Importantly, the functions of this peptide hormone are solely dependent on its *n*-octanoylation at Ser-3 by GOAT.^[16] Of further significance, ghrelin is the only known peptide to contain an *n*-

[*] Dr. A. L. Garner, Prof. K. D. Janda
Departments of Chemistry and Immunology
The Skaggs Institute for Chemical Biology and
The Worm Institute for Research and Medicine
The Scripps Research Institute
10550 North Torrey Pines Road, La Jolla, CA 92037 (USA)
Fax: (+1) 858-784-2595
E-mail: kdjanda@scripps.edu

[**] This work was supported by the Skaggs Institute for Chemical Biology (K.D.J.) and by the NIH (postdoctoral fellowship F32-DK083179 to A.L.G.). We are grateful to Damian Ekiert for assistance with baculovirus expression, Prof. M. G. Finn for helpful discussions, and Vu Hong for donation of THPTA.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201003387>.




Figure 2. GOAT-catalyzed *n*-octanoyl transfer to ghrelin.

octanoyl post-translational modification,^[16] thus, this peptide is most likely the only substrate for GOAT and inhibitors of this enzyme should be highly specific. As our group has previously examined a vaccine-based approach for sequestering^[17] and/or catalyzing the hydrolysis^[18] of ghrelin using monoclonal antibodies as anti-obesity strategies, we were also interested in establishing a small-molecule-based program targeting GOAT since currently no validated chemical probes for this enzyme have been reported.^[19a]

To date, only two *in vitro* assay systems have been reported for screening GOAT activity.^[19] Similar to other acyltransferase assays, both rely on autoradiographic methods and neither is amenable to high-throughput screening. Since we envisioned establishing a library-based screening effort against GOAT and the current screening assays impede such efforts, we wanted to use our cat-ELCCA approach to design a robust assay for GOAT. Our assay design is shown in Figure 3. In brief, a biotinylated ghrelin peptide immobilized on a streptavidin-modified microtiter plate would be incubated with GOAT and alkynyl-tagged *n*-octynoyl-CoA for the acyl transfer reaction; the wells would then be subjected to click-chemistry conditions. For the azide-labeled enzyme, we chose horseradish peroxidase (HRP), as activated HRP derivatives for bioconjugation and fluorescent/colorimetric substrates for this enzyme are commercially available. Following the click reaction, the HRP-triazole product would be detected using amplex red as a fluorogenic substrate in the presence of hydrogen peroxide to provide catalytic fluorescence signal amplification of the octynoyl ester–HRP triazole product concentration.

To test the applicability of cat-ELCCA to the GOAT problem, we first isolated the GOAT enzyme. As previously described,^[19a] Sf9 insect cells were infected with a recombinant baculovirus encoding mouse GOAT for protein overexpression. Since GOAT is a transmembrane protein and efforts to purify this enzyme to homogeneity have previously failed,^[19a] the crude GOAT-containing membrane fraction was isolated by ultracentrifugation techniques, and the resultant membrane fraction was used as such for all subsequent assays. The acyltransferase activity of the isolated membrane-bound GOAT was confirmed with a control reaction using ghrelin(1–28) and *n*-octanoyl-CoA. Based on

known HPLC traces of *n*-octanoyl-ghrelin(1–28) and the unacylated peptide, the activity of GOAT in this crude extract was confirmed (data not shown). Additionally, no octanoyl transfer was observed in uninfected Sf9 cell membranes (data not shown).

Next, we turned our attention toward the preparation of suitable ghrelin and azido-HRP substrates. For an immobilized ghrelin substrate, we chose a ghrelin(1–5) pentapeptide containing a C-terminal biotin, which was synthesized using solid-phase peptide synthesis (see the Supporting Information). Ghrelin(1–5) was chosen as this has been shown to be the minimum recognition sequence for both GOAT activity^[19a] and ghrelin's receptor, growth hormone secretagogue receptor 1a (GHS-R1a),^[20] and is synthetically tractable for high-throughput efforts. As anticipated, this ghrelin substrate was found to be recognized by GOAT (HPLC data not shown). To prepare the azido-tagged HRP, we used an aldehyde-functionalized peroxidase as an amine-reactive HRP, and this activated HRP was treated with 11-azido-3,6,9-trioxaundecan-1-amine to obtain azido-tagged HRP (see the Supporting Information).

With the assay components in hand, we set out to test our design hypothesis. The biotinylated ghrelin(1–5)pentapeptide was first immobilized to the wells of a streptavidin-coated microtiter plate (96-well, black), which was to be followed with the GOAT-catalyzed acyl transfer reaction. Here, the solid-supported ghrelin substrate was first incubated with membrane-bound GOAT ($\approx 50 \mu\text{g}$) in HEPES buffer (50 mM pH 7.0) for 5 min at 37°C. Palmitoyl-CoA (50 μM) and *n*-octynoyl-CoA (1 μM) were then added to the mixture to initiate the reaction. Palmitoyl-CoA was included as a competing fatty acid thioester to reduce any background hydrolysis of *n*-octynoyl-CoA due to esterases in the crude membrane extract.^[19a] The click reaction was then performed with azido-tagged HRP (Figure 3A). It is important to note here that in model studies all attempts to use the commercially available tris[(1-benzyl-1*H*-1,2,3-triazol-4-yl)methyl]amine (TBTA)^[21] ligand at low concentrations of substrate failed; however, use of the more hydrophilic ligand, tris[(3-hydroxypropyl-1*H*-1,2,3-triazol-4-yl)methyl]amine (THPTA) (Figure 3A)^[22] recently disclosed by the Finn group, resulted in consistently successful coupling regardless of substrate




Figure 3. cat-ELCCA for screening GOAT activity. A) Assay design. B) Proof-of-concept data. ++ = Sample treated with both GOAT-containing membranes and *n*-octynoyl-CoA. RFU = normalized relative fluorescence units at 585 nm.

concentration (data not shown). After the click reaction, the wells were treated with amplex red and hydrogen peroxide, and the resulting resorufin fluorescence was measured ($\lambda_{\text{ex}} = 560 \text{ nm}$, $\lambda_{\text{em}} = 585 \text{ nm}$). As shown in Figure 3B, our assay design was successful, and under these conditions a 7.5-fold fluorescence enhancement (raw fluorescence data) was observed over wells not treated with GOAT or *n*-octynoyl-CoA. It is important to note here that this is the first time that GOAT has been shown to accept an alkynyl-CoA substrate.

Given these successful results, we next characterized the GOAT-catalyzed acyl transfer reaction using our cat-ELCCA system. We first examined the time dependence of *n*-octanoyl transfer to the immobilized ghrelin(1–5)pentapeptide. As Figure 4A shows, the formation of *n*-octynoyl-ghrelin(1–5)pentapeptide was linear with time for ca. 2 min. The assay was also linear with respect to the amount of GOAT-containing membranes (up to ca. 25 μg) added to the wells (Figure 4B). It is important to note here that beyond the range shown in Figure 4B, a slight decrease in product formation was observed, which is likely due to an increased concentration of competing esterases in the crude membrane preparation. As Figure 4C and D show, the assay also exhibited saturation kinetics with respect to the concentrations of *n*-octynoyl-CoA and immobilized ghrelin(1–5)pentapeptide.

Because we envision that this assay will be used to screen for antagonists against this potential anti-obesity target, it was also important to determine the apparent K_m values for GOAT. Initial velocities were measured for varying concentrations of *n*-octynoyl-CoA and immobilized ghrelin(1–5)pentapeptide. Nonlinear regression (GraphPad Prism

v5.0a) showed that the data fit Michaelis–Menten kinetics (see the Supporting Information). The apparent K_m values were 67.5 nM and 99.8 nM for *n*-octynoyl-CoA and the immobilized ghrelin(1–5)pentapeptide, respectively. In addition, to assess the suitability of cat-ELCCA for high-throughput screening, we also determined the signal-to-noise ratio (S/N), signal-to-background ratio (S/B) and Z' factor, a statistical parameter for scoring assay performance.^[23] The S/N ratio was 24, the S/B ratio was 3.5 and the Z' factor was 0.63 (see the Supporting Information), indicating the potential of our assay for high-throughput screening. Most important of these statistical indicators is the Z' factor, which is reflective of both dynamic range and data variation associated with the signal measurement, and Z' values between 0.5 and 1 are typically regarded as excellent assays.

In summary, we have described a conceptually new enzyme assay based on cat-ELISA, catalytic assay using enzyme-linked click-chemistry assay, or cat-ELCCA. By utilizing an enzyme-linked click-chemistry substrate, we are able to arm the assay with catalytic signal amplification necessary for ultrasensitive detection. Using this assay technology, we developed a screening system for the acyltransferase of ghrelin, ghrelin *O*-acyltransferase (GOAT), that is efficient, sensitive, and inexpensive, and importantly, obviates the need for radioisotopes. As GOAT has been implicated as a potential anti-obesity target and much more is still to be learned about this recently disclosed MBOAT family member, we envision that cat-ELCCA will be useful for discovering antagonists and chemical probes for this enzyme, a goal that we are currently pursuing. Finally, as the

immobilized peptide and alkynyl substrates are modular, cat-ELCCA should find additional uses with other fatty acid acyltransferases, such as myristoyltransferases and palmitoyltransferases, other biologically relevant acyltransferases (e.g. histone acetyltransferases, *N*-acetyltransferases), and the discovery of previously unidentified proteins with acyltransferase activity.




Figure 4. Characterization of GOAT acyltransferase activity using cat-ELCCA. A) Time dependence. B) Dependence on the amount of GOAT membranes. C) Dependence on *n*-octynoyl-CoA concentration. D) Dependence on immobilized ghrelin(1–5)pentapeptide concentration. RFU = normalized relative fluorescence units at 585 nm.

Experimental Section

Membrane-bound GOAT (ca. 50 μg) and HEPES buffer (50 mM, pH 7.0) were added to wells of a black, 96-well Reacti-Bind Streptavidin High-Binding Capacity microtiter plate containing immobilized ghrelin(1–5)pentapeptide, and the plate was incubated at 37°C for 5 min. Palmitoyl-CoA (50 μM) and *n*-octynoyl-CoA (1.0 μM) were then added to the mixture to initiate the enzyme-catalyzed reaction (total volume 100 μL), and the plate was incubated at 37°C for another 5 min. The

GOAT reaction mixture was then removed, and the wells were washed with TBST ($3 \times 200 \mu\text{L}$) followed by PBS (pH 7.4) ($3 \times 200 \mu\text{L}$). Fresh PBS (pH 7.4), HRP- N_3 ($1.0 \mu\text{M}$), CuSO_4 ($100 \mu\text{M}$), THPTA ($500 \mu\text{M}$), and sodium ascorbate (5 mM) were then added (total volume $100 \mu\text{L}$), and the plate was covered and allowed to shake at 25°C for 2 h. The click reaction mixture was then removed, and the wells were washed again with TBST ($3 \times 200 \mu\text{L}$) and PBS (pH 7.4) ($3 \times 200 \mu\text{L}$). For detection, $100 \mu\text{L}$ of amplex red/ H_2O_2 solution (QuantaRed Enhanced Chemifluorescent HRP Substrate kit) was added to each well, and the fluorescence ($\lambda_{\text{ex}} = 560 \text{ nm}$, $\lambda_{\text{em}} = 585 \text{ nm}$) was measured over time (ca. 10 min) on a SpectraMax M2^o Microplate Reader (Molecular Devices). A standard curve was generated using known concentrations of HRP- N_3 in the reaction buffer.

Received: June 4, 2010

Published online: September 15, 2010

Keywords: alkynes · azides · enzymes · peptides

- [1] W. J. Blaedel, R. C. Boguslaski, *Anal. Chem.* **1978**, *50*, 1026–1032.
- [2] a) L. Zhu, V. M. Lynch, E. V. Anslyn, *Tetrahedron* **2004**, *60*, 7267–7275; b) Q. Wu, E. V. Anslyn, *J. Am. Chem. Soc.* **2004**, *126*, 14682–14683; c) Q. Wu, E. V. Anslyn, *J. Mater. Chem.* **2005**, *15*, 2815–2819; d) R. J. T. Houk, E. V. Anslyn, *New J. Chem.* **2007**, *31*, 729–735; e) N. C. Gianneschi, S. T. Nguyen, C. A. Mirkin, *J. Am. Chem. Soc.* **2005**, *127*, 1644–1645; f) M. S. Masar III, N. C. Gianneschi, C. G. Oliveri, C. L. Stern, S. T. Nguyen, C. A. Mirkin, *J. Am. Chem. Soc.* **2007**, *129*, 10149–10158; g) N. Graf, M. Göritz, R. Krämer, *Angew. Chem.* **2006**, *118*, 4117–4119; *Chem. Int. Ed.* **2006**, *45*, 4013–4015; h) N. Graf, R. Krämer, *Chem. Commun.* **2006**, 4375–4376; i) F. Song, A. L. Garner, K. Koide, *J. Am. Chem. Soc.* **2007**, *129*, 12354–12355; j) A. L. Garner, K. Koide, *J. Am. Chem. Soc.* **2008**, *130*, 16472–16473; k) A. L. Garner, F. Song, K. Koide, *J. Am. Chem. Soc.* **2009**, *131*, 5163–5171.
- [3] a) B. Rotman, *Proc. Natl. Acad. Sci. USA* **1961**, *47*, 1981–1991; b) J.-L. Reymond, V. S. Fluxà, N. Maillard, *Chem. Commun.* **2009**, 34–46.
- [4] M. D. Resh, *Methods* **2006**, *40*, 191–197.
- [5] a) A. S. Varner, M. L. De Vos, S. P. Creaser, B. R. Peterson, C. D. Smith, *Anal. Biochem.* **2002**, *308*, 160–167; b) A. S. Varner, C. E. Ducker, Z. Xia, Y. Zhuang, M. L. De Vos, C. D. Smith, *Biochem. J.* **2003**, *373*, 91–99; c) A. T. Lada, M. Davis, C. Kent, J. Chapman, H. Tomoda, S. Omura, L. L. Rudel, *J. Lipid Res.* **2004**, *45*, 378–386; d) C. E. Ducker, L. K. Griffel, R. A. Smith, S. N. Keller, Y. Zhuang, Z. Xia, J. D. Diller, C. D. Smith, *Mol. Cancer Ther.* **2006**, *5*, 1647–1659.
- [6] a) H. C. Hang, E.-J. Geutjes, G. Grotenberg, A. M. Pollington, M. J. Bijlmakers, H. L. Ploegh, *J. Am. Chem. Soc.* **2007**, *129*, 2744–2745; b) A. Raghavan, G. Charron, J. Flexner, H. C. Hang, *Bioorg. Med. Chem. Lett.* **2008**, *18*, 5982–5986; c) B. R. Martin, B. F. Cravatt, *Nat. Methods* **2009**, *6*, 135–138; d) G. Charron, M. M. Zhang, J. S. Yount, J. Wilson, A. Raghavan, E. Shamir, H. C. Hang, *J. Am. Chem. Soc.* **2009**, *131*, 4967–4975; e) R. N. Hannoush, N. Arenas-Ramirez, *ACS Chem. Biol.* **2009**, *4*, 581–587; f) M. M. Zhang, L. K. Tsou, G. Charron, A. Raghavan, H. C. Hang, *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 8627–8632.
- [7] a) V. V. Rostovtsev, L. G. Green, V. V. Fokin, K. B. Sharpless, *Angew. Chem.* **2002**, *114*, 2708–2711; *Angew. Chem. Int. Ed.* **2002**, *41*, 2596–2599; b) C. W. Tornøe, C. Christensen, M. Meldal, *J. Org. Chem.* **2002**, *67*, 3057–3064; c) M. Meldal, C. W. Tornøe, *Chem. Rev.* **2008**, *108*, 2952–3015.
- [8] Q. Wang, T. R. Chan, R. Hilgraf, V. V. Fokin, K. B. Sharpless, M. G. Finn, *J. Am. Chem. Soc.* **2003**, *125*, 3192–3193.
- [9] a) A. Krasinski, Z. Radic, R. Manetsch, J. Raushel, P. Taylor, K. B. Sharpless, H. C. Kolb, *J. Am. Chem. Soc.* **2005**, *127*, 6686–6692; b) V. P. Mocharla, B. Colasson, L. V. Lee, S. Röper, K. B. Sharpless, C.-H. Wong, H. C. Kolb, *Angew. Chem.* **2005**, *117*, 118–122; *Angew. Chem. Int. Ed.* **2005**, *44*, 116–120; c) R. Srinivasan, J. Li, S. Ling Ng, K. A. Kalesh, S. Q. Yao, *Nat. Protoc.* **2007**, *2*, 2655–2664.
- [10] a) G. B. Wisdom, *Clin. Chem.* **1976**, *22*, 1243–1255; b) J. P. Gosling, *Clin. Chem.* **1990**, *36*, 1406–1427.
- [11] D. S. Tawfik, B. S. Green, R. Chap, M. Sela, Z. Eshhar, *Proc. Natl. Acad. Sci. USA* **1993**, *90*, 373–377.
- [12] Immobilized substrates have previously been utilized in click chemistry, see M. C. Bryan, F. Fazio, H.-K. Lee, C.-Y. Huang, A. Chang, M. D. Best, D. A. Calarese, O. Blixt, J. C. Paulson, D. Burton, I. A. Wilson, C.-H. Wong, *J. Am. Chem. Soc.* **2004**, *126*, 8640–8641.
- [13] a) J. Yang, M. S. Brown, G. Liang, N. V. Grishin, J. L. Goldstein, *Cell* **2008**, *132*, 387–396; b) J. A. Gutierrez, P. J. Solenberg, D. R. Perkins, J. A. Willency, M. D. Knierman, Z. Jin, D. R. Witcher, S. Luo, J. E. Onyia, J. E. Hale, *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 6320–6325.
- [14] K. Hofmann, *Trends Biochem. Sci.* **2000**, *25*, 111–112.
- [15] a) M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, K. Kangawa, *Nature* **1999**, *402*, 656–660; b) M. H. Tschöp, D. L. Smiley, M. L. Heiman, *Nature* **2000**, *407*, 908–913; c) T. R. Castañeda, J. Tong, R. Datta, M. Culler, M. H. Tschöp, *Front. Neuroendocrinol.* **2010**, *31*, 44–60.
- [16] M. Kojima, K. Kangawa, *Physiol. Rev.* **2005**, *85*, 495–522.
- [17] E. P. Zorrilla, S. Iwasaki, J. A. Moss, J. Chang, J. Otsuji, K. Inoue, M. M. Meijler, K. D. Janda, *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 13226–13231.
- [18] A. V. Mayorov, N. Amara, J. Y. Chang, J. A. Moss, M. S. Hixon, D. I. Ruiz, M. M. Meijler, E. P. Zorrilla, K. D. Janda, *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 17487–17492.
- [19] An initial report of product-based inhibitors has been described in Ref. [19a]; a) J. Yang, T.-J. Zhao, J. L. Goldstein, M. S. Brown, *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 10750–10755; b) H. Ohgusu, K. Shirouzu, Y. Nakamura, Y. Nakashima, T. Ida, T. Sato, M. Kojima, *Biochem. Biophys. Res. Commun.* **2009**, *386*, 153–158.
- [20] a) M. A. Bednarek, S. D. Feighner, S.-S. Pong, K. K. McKee, D. L. Hreniuk, M. V. Silva, V. A. Warren, A. D. Howard, L. H. Y. Van der Ploeg, J. V. Heck, *J. Med. Chem.* **2000**, *43*, 4370–4376; b) M. Matsumoto, H. Hosoda, Y. Kitajima, N. Morozumi, Y. Minamitake, S. Tanaka, H. Matsuo, M. Kojima, Y. Hayashi, K. Kangawa, *Biochem. Biophys. Res. Commun.* **2001**, *287*, 142–146.
- [21] T. R. Chan, R. Hilgraf, K. B. Sharpless, V. V. Fokin, *Org. Lett.* **2004**, *6*, 2853–2855.
- [22] V. Hong, S. I. Presolski, C. Ma, M. G. Finn, *Angew. Chem.* **2009**, *121*, 10063–10067; *Angew. Chem. Int. Ed.* **2009**, *48*, 9879–9883.
- [23] J.-H. Zhang, T. D. Y. Chung, K. R. Oldenburg, *J. Biomol. Screening* **1999**, *4*, 67–73.